The National Healthcare Security Administration (NHSA) has issued the “Procedures for Identification of Drug and Medical Insurance Catalogue Attribution (Trial)”, which takes effect immediately.
The program is designed to address instances where a drug’s name or dosage form may not align with the National Reimbursement Drug List (NRDL) due to renaming or aliasing, yet stakeholders believe it should be recognized as either a drug within or outside the NRDL according to the regulations.
Pharmaceutical companies and medical institutions, among other relevant parties, can file objections concerning the NRDL attribution of drugs as indicated in the current “Classification and Code of Medical Insurance Drugs”. They may independently apply to the NHSA for the recognition of the drug’s NRDL attribution. The attribution identification will be conducted on a quarterly basis, and applications received in the previous quarter that meet the criteria can be identified and temporarily implemented in special cases. The same drug variety will not be subject to repeated demonstrations unless new significant evidence is provided.- Flcube.com
